Default company panoramic image
B3b05581 256c 49a0 ad06 279d7343c87d

Alpha Source

proprietary alpha particle accelerator for radioisotopes production, filling a supply void and creating a unique investment opportunity

  • Stage Product In Development
  • Industry Biotechnology
  • Location Los Angeles, CA, USA
  • Currency USD
  • Founded January 2007
  • Employees 4

Company Summary

Alpha Source's patent ion beam is at the heart of a novel radioisotope production method which will be able to solve many of the supply shortages faced in the industry. This unique process allows for very cost effective production of highly sought after isotopes with often much less long lived radioactive waste then conventional methods. The main customer base will be radiopharmaceutical manufacturers - Covidien, Lantheus and Cardinal Health


  • Default avatar
    Howard C Lewin

    is a leader in the field of nuclear cardiology. He has training in both Cardiology and Nuclear Medicine and has experience as both an academic physician as well as the business of (nuclear) medicine. Dr. Lewin built a large nuclear cardiology practice and over the past few years, adapting to market forces, started a successful in-office cardiac PET business.

  • Default avatar
    Glenn Rosenthal

    Dr. Rosenthal is an accomplished UCLA physicist, lecturer, consultant, and researcher, who served as Principal Investigator on numerous successful projects and was awarded grants from NIH, NSF, DARPA, DOE, Siemens Nuclear Power, and others. To support him, Alpha Source has assembled a talented team of scientists and entrepreneurs.

  • Default avatar
    Alan R Fritzberg
    Board of Directors

    A pioneer in the nuclear medicine field, spending nine years at the universities of Colorado and Utah from 1976 to 1984 before co-founding NeoRx Corporation in Seattle, where he worked for many years as Vice President and Scientific Director. Dr. Fritzberg, along with his research group, developed technetium-99m MAG3 for kidney function evaluation. He was also involved with the development of improved tumor targeting strategies and in-licensing